Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

WORLD TECHNOLOGY NETWORK AWARD

31 Oct 2011 07:00

RNS Number : 1066R
Angle PLC
31 October 2011
 



 

 

For immediate release

31 October 2011

 

ANGLE plc ("the Company")

 

WORLD TECHNOLOGY NETWORK AWARD

 

 

ANGLE plc ("ANGLE"), which focuses on the commercialisation of technology, is delighted to announce that its Middle East Director, Dr Athar Osama has been awarded the prestigious World Technology Network (WTN) award and has been elected as a fellow of the WTN.

 

ANGLE employee, Dr Osama is the first Pakistani to receive the WTN award, which are seen as the "Oscars of Science and Technology". With this award, WTN has recognised www.Muslim-Science.com, which was founded by Dr Osama as an agent of change.

 

Muslim-Science.com is designed as a platform for a dialogue among Muslims and between Muslims and other communities about the state of science and technology in the Muslim World and the influence of Muslim faith on the former.

 

The Previous WTN award winners include Al Gore (US former Vice President), Mohammad Yunus (founder of Grameen Bank), Mark Zuckurberg (Facebook founder), Larry Page (Google) and Tim Berners-Lee (Inventor of Internet).

 

Dr Athar Osama, Director of Middle East and Asia for ANGLE commented: 

"I am honoured to have received this award. There is major potential in connecting Muslim technology to Western markets and vice versa. The Muslim World that has for too long now been only a consumer of knowledge and technology generated in the West now has an opportunity to leapfrog several stages of development and become both an intelligent user and producer of scientific knowledge and technological innovation. Many Islamic countries, including Saudi Arabia, Qatar, UAE, Malaysia, Pakistan, Iran, Jordan, and Egypt have, in recent years, shown remarkable ambition to invest heavily in science and innovation and ANGLE is pleased to have played our part in laying the foundation of a science and innovation revolution in the Islamic World."

 

Andrew Newland, Chief Executive of ANGLE commented: 

"We are very proud of Athar's success. Dialogue about science and technology is an excellent way to improve understanding between the Muslim and non-Muslim communities and ANGLE is delighted to have supported this communication through our extensive involvement in the Middle East over the last several years."

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8350

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAEEEDFLFFAF
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.